Literature DB >> 22246648

Biomolecular chemistry of isopropyl fibrates.

Ganesaratnam K Balendiran1, Niharika Rath, Amanda Kotheimer, Chad Miller, Matthias Zeller, Nigam P Rath.   

Abstract

Isopropyl 2-[4-(4-chlorobenzoyl)-phenoxy]-2-methylpropanoic acid and isopropyl 2-(4-chlorophenoxy)-2-methylpropanoate, also known as fenofibrate and isopropyl (iPr) clofibrate, are hypolipidemic agents of the fibrate family. In a previously reported triclinic structure of fenofibrate (polymorph I), the methyl groups of the iPr moiety are located symmetrically about the carboxylate group. We report a new monoclinic form (polymorph II) of fenofibrate and a first structural description of iPr clofibrate, and in these the methyl groups are placed asymmetrically about the carboxylate group. In particular, the dihedral (torsion) angle between the hydrogen atom on the secondary C and the C atom of the carboxyl group makes a 2.74° angle about the ester O···C bond in the symmetric fenofibrate structure of polymorph I, whereas the same dihedral angle is 45.94° in polymorph II and -30.9° in the crystal structure of iPr clofibrate. Gas-phase density functional theory (DFT) geometry minimizations of fenofibrate and iPr clofibrate result in lowest energy conformations for both molecules with a value of about ±30° for this same angle between the OC-O-C plane and the C-H bond of the iPr group. A survey of crystal structures containing an iPr ester group reveals that the asymmetric conformation is predominant. Although the hydrogen atom on the secondary C atom of the iPr group is located at a comparable distance from the carbonyl oxygen in the symmetric and asymmetric fenofibrate (2.52 and 2.28 Å) and the iPr clofibrate (2.36 Å) structures, this hydrogen atom participates in a puckered five-membered ring arrangement in the latter two that is unlike the planar arrangement found in symmetric fenofibrate (polymorph I). Polar molecular surface area values indicate fenofibrate and iPr clofibrate are less able to act as acceptors of hydrogen bonds than their corresponding acid derivatives. Surface area calculations show that dynamic polar molecular surface area values of the iPr esters of the fibrates are lower than those of their acids, implying that the fibrates have better membrane permeability and a higher absorbability and hence are better prodrugs when these agents need to be orally administered.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246648      PMCID: PMC3350796          DOI: 10.1002/jps.23040

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  30 in total

1.  Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography.

Authors:  B Streel; P Hubert; A Ceccato
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-06-09

2.  Quantitative Ranking of Crystal Packing Modes by Systematic Calculations on Potential Energies and Vibrational Amplitudes of Molecular Dimers.

Authors:  A Gavezzotti
Journal:  J Chem Theory Comput       Date:  2005-09       Impact factor: 6.006

3.  Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity.

Authors:  P Stenberg; K Luthman; H Ellens; C P Lee; P L Smith; A Lago; J D Elliott; P Artursson
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

4.  Predicting drug absorption from molecular surface properties based on molecular dynamics simulations.

Authors:  L H Krarup; I T Christensen; L Hovgaard; S Frokjaer
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

5.  Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.

Authors:  K Palm; K Luthman; A L Ungell; G Strandlund; F Beigi; P Lundahl; P Artursson
Journal:  J Med Chem       Date:  1998-12-31       Impact factor: 7.446

Review 6.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

7.  Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.

Authors:  Fabien Forcheron; Ana Cachefo; Sylvie Thevenon; Claudie Pinteur; Michel Beylot
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

8.  Fibrates inhibit aldose reductase activity in the forward and reverse reactions.

Authors:  Ganesaratnam K Balendiran; Balakrishnan Rajkumar
Journal:  Biochem Pharmacol       Date:  2005-10-13       Impact factor: 5.858

Review 9.  Fibrates in the chemical action of daunorubicin.

Authors:  Ganesaratnam K Balendiran
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

10.  A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.

Authors:  Jeffrey Thomas; Kelli S Bramlett; Chahrzad Montrose; Patricia Foxworthy; Patrick I Eacho; Denis McCann; Guoqing Cao; Anton Kiefer; Jeff McCowan; Kuo-Long Yu; Timothy Grese; William W Chin; Thomas P Burris; Laura F Michael
Journal:  J Biol Chem       Date:  2002-11-18       Impact factor: 5.157

View more
  5 in total

1.  Formation of Organic Molecular Nanocrystals under Rigid Confinement with Analysis by Solid State NMR.

Authors:  X Yang; T C Ong; V K Michaelis; S Heng; J Huang; R G Griffin; A S Myerson
Journal:  CrystEngComm       Date:  2014-10-21       Impact factor: 3.545

Review 2.  Use of fibrates in the metabolic syndrome: A review.

Authors:  Kate E Shipman; Richard C Strange; Sudarshan Ramachandran
Journal:  World J Diabetes       Date:  2016-03-10

3.  Molecular dynamics of fibric acids.

Authors:  Chad Miller; Steven Schildcrout; Howard Mettee; Ganesaratnam Balendiran
Journal:  Eur J Chem       Date:  2022-06-30

4.  Towards controlling the crystallisation behaviour of fenofibrate melt: triggers of crystallisation and polymorphic transformation.

Authors:  Pratchaya Tipduangta; Khaled Takieddin; László Fábián; Peter Belton; Sheng Qi
Journal:  RSC Adv       Date:  2018-04-10       Impact factor: 4.036

5.  Characterization of WY 14,643 and its Complex with Aldose Reductase.

Authors:  Michael R Sawaya; Malkhey Verma; Vaishnavi Balendiran; Nigam P Rath; Duilio Cascio; Ganesaratnam K Balendiran
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.